New research indicates that individuals who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who halt traditional diet and exercise programs.
Published data in a major medical journal points out that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments must be informed of the potential of fast rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery suggests a return to starting mass in about a year and a half.
Weighing Treatments
The study, which reviewed 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
The team note that people who shed pounds through dieting generally have a more gradual creep back—approximately 0.1 kg a month—once they finish.
Understanding the Fast Regain
Nutrition scientists suggest the way of the injections explains the heightened regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating far more likely."
A Chronic Condition?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, due to the high risk of relapse, the treatment is often ongoing.
This view is echoed by drug manufacturers, who say that the results "highlight the long-term nature of obesity," similar to managing diseases like hypertension.
User Experiences
People who have come off the medication report a powerful return of appetite.
"I experienced a switch that goes on and I was suddenly extremely hungry," described an individual.
The struggle is exacerbated if patients have not established lasting dietary or behavioural modifications during treatment.
Growing Interest
Figures suggest that a significant number of people in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Use is greater among women than men.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, clinicians caution that while the jabs are effective tools for weight loss, they are not a standalone cure and long-term success likely depends on ongoing behavioural management.
